You are here
C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.
Tuesday,2012-11-06 12:10 America/Los_Angeles — eenright
| Title | C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Pierce, BL, Biggs, ML, DeCambre, M, Reiner, AP, Li, C, Fitzpatrick, A, Carlson, CS, Stanford, JL, Austin, MA |
| Journal | Cancer Causes Control |
| Volume | 20 |
| Issue | 7 |
| Pagination | 1193-203 |
| Date Published | 2009 Sep |
| ISSN | 1573-7225 |
| Keywords | African Americans, Aged, Aged, 80 and over, Biomarkers, C-Reactive Protein, European Continental Ancestry Group, Humans, Inflammation, Interleukin-6, Male, Polymorphism, Single Nucleotide, Prospective Studies, Prostatic Neoplasms, Risk Factors |
| Abstract | <p>Inflammation is believed to play a role in prostate cancer (PCa) etiology, but it is unclear whether inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6) associate with PCa risk in older men. Using Cox regression, we assessed the relationship between baseline concentrations of CRP and IL-6 and the subsequent PCa risk in the Cardiovascular Health Study, a population-based cohort study of mostly European American men of ages >64 years (n = 2,234; mean follow-up = 8.7 years; 215 incident PCa cases). We also tested associations between CRP and IL-6 tagSNPs and PCa risk, focusing on SNPs that are known to associate with circulating CRP and/or IL-6. Neither CRP nor IL-6 blood concentrations was associated with PCa risk. The C allele of IL-6 SNP rs1800795 (-174), a known functional variant, was associated with increased risk in a dominant model (HR = 1.44; 95% CI = 1.03-2.01; p = 0.03), but was not statistically significant after accounting for multiple tests (permutation p = 0.21). Our results suggest that circulating CRP and IL-6 do not influence PCa risk. SNPs at the CRP locus are not associated with PCa risk in this cohort, while the association between rs1800795 and PCa risk warrants further investigation.</p> |
| DOI | 10.1007/s10552-009-9320-4 |
| Alternate Journal | Cancer Causes Control |
| PubMed ID | 19267250 |
| PubMed Central ID | PMC2846958 |
| Grant List | N01-HC-85085 / HC / NHLBI NIH HHS / United States N01-HC-85081 / HC / NHLBI NIH HHS / United States N01-HC-85086 / HC / NHLBI NIH HHS / United States N01-HC-85082 / HC / NHLBI NIH HHS / United States N01 HC-55222 / HC / NHLBI NIH HHS / United States R25-CA94880 / CA / NCI NIH HHS / United States N01-HC-85079 / HC / NHLBI NIH HHS / United States N01-HC-85083 / HC / NHLBI NIH HHS / United States N01-HC-75150 / HC / NHLBI NIH HHS / United States N01-HC-85080 / HC / NHLBI NIH HHS / United States |